Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968339 | 1.00 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL266899 | 1.00 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL1740902 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL31545209 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL1740903 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL3460220 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL3027061 | 0.85 | APLNR (0.59) | HTR2A | |
| Hydrochloric Acid SCHEMBL29542459 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL3486527 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL30861235 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12239632-B2 | Asymmetric allyl tryptamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240408038-A1 | SUBSTITUTED PHENYLALKYLAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560486-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012122412-A2 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133347-A1 | COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239632-B2 | Asymmetric allyl tryptamines | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR1A 4/4885HTR2C 6/4885 |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | HTR2A 25/4885HTR1A 37/4885HTR2C 6/4885 |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885HTR1A 29/4885HTR2C 44/4885 |
| US-20250195471-A1 | ASYMMETRIC ALLYL TRYPTAMINES | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR1A 4/4885HTR2C 6/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | HTR2A 4/4885HTR1A 5/4885HTR2C 15/4885 |
| US-20240408038-A1 | SUBSTITUTED PHENYLALKYLAMINES | PNMT, HTR2A, SLC18A2 | HTR2A 2/4885HTR1A 4/4885HTR2C 8/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885HTR1A 29/4885HTR2C 44/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | HTR2A 823/4885HTR1A 727/4885HTR2C 673/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | HTR2A 2491/4885HTR1A 1360/4885HTR2C 1619/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | HTR2A 375/4885HTR1A 293/4885HTR2C 227/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 9/4885HTR1A 11/4885HTR2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.